Agenus (AGEN) Stock Forecast, Price Target & Predictions
AGEN Stock Forecast
Agenus stock forecast is as follows: an average price target of $8.00 (represents a 97.04% upside from AGEN’s last price of $4.06) and a rating consensus of 'Hold', based on 4 wall street analysts offering a 1-year stock forecast.
AGEN Price Target
The average price target for Agenus (AGEN) is $8.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $9.00 to $7.00. This represents a potential 97.04% upside from AGEN's last price of $4.06.
AGEN Analyst Ratings
According to 4 Wall Street analysts, Agenus's rating consensus is 'Hold'. The analyst rating breakdown for AGEN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (25.00%), 3 'Hold' (75.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Agenus Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 19, 2024 | Biren Amin | Jefferies | $7.00 | $5.99 | 16.86% | 72.41% |
| Jul 19, 2024 | Colleen Kusy | Robert W. Baird | $8.00 | $7.30 | 9.59% | 97.04% |
| Jul 18, 2024 | Emily Bodnar | H.C. Wainwright | $9.00 | $7.98 | 12.85% | 121.67% |
| Jul 01, 2024 | Emily Bodnar | H.C. Wainwright | $40.00 | $16.75 | 138.81% | 885.22% |
The latest Agenus stock forecast, released on Jul 19, 2024 by Biren Amin from Jefferies, set a price target of $7.00, which represents a 16.86% increase from the stock price at the time of the forecast ($5.99), and a 72.41% increase from AGEN last price ($4.06).
Agenus Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $16.00 |
| Last Closing Price | $4.06 | $4.06 | $4.06 |
| Upside/Downside | -100.00% | -100.00% | 294.09% |
In the current month, the average price target of Agenus stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Agenus's last price of $4.06. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 14, 2024 | B. Riley | Buy | Buy | Hold |
| Jul 19, 2024 | Jefferies | - | Hold | Downgrade |
| Jul 18, 2024 | William Blair | - | Market Perform | Downgrade |
| Jul 18, 2024 | H.C. Wainwright | Buy | Neutral | Downgrade |
| Jul 01, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Agenus's last stock rating was published by B. Riley on Aug 14, 2024. The company gave AGEN a "Buy" rating, the same as its previous rate.
Agenus Financial Forecast
Agenus Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $83.80M | $24.31M | $25.30M | $22.90M | $28.39M | $22.77M | $20.93M | $25.94M | $20.26M | $252.95M | $10.73M | $11.72M | $31.26M | $14.83M | $26.95M | $15.13M | $34.50M | $19.94M |
| Avg Forecast | $96.42M | $92.53M | $86.73M | $80.91M | $43.94M | $43.91M | $43.89M | $43.89M | $41.38M | $33.48M | $63.48M | $47.17M | $47.05M | $24.33M | $24.13M | $22.98M | $17.83M | $20.69M | $18.70M | $11.80M | $37.74M | $183.10M | $20.41M | $14.53M | $16.23M | $14.00M | $9.33M | $12.35M | $13.03M | $15.60M |
| High Forecast | $96.42M | $92.53M | $86.73M | $80.91M | $43.94M | $43.91M | $43.89M | $43.89M | $41.38M | $54.54M | $63.48M | $47.17M | $64.49M | $24.33M | $24.13M | $22.98M | $17.83M | $20.69M | $18.70M | $11.80M | $37.74M | $183.10M | $20.41M | $14.53M | $16.23M | $14.00M | $9.33M | $12.35M | $13.03M | $15.60M |
| Low Forecast | $96.42M | $92.53M | $86.73M | $80.91M | $43.94M | $43.91M | $43.89M | $43.89M | $41.38M | $22.10M | $63.48M | $47.17M | $22.42M | $24.33M | $24.13M | $22.98M | $17.83M | $20.69M | $18.70M | $11.80M | $37.74M | $183.10M | $20.41M | $14.53M | $16.23M | $14.00M | $9.33M | $12.35M | $13.03M | $15.60M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.78% | 1.00% | 1.05% | 1.00% | 1.59% | 1.10% | 1.12% | 2.20% | 0.54% | 1.38% | 0.53% | 0.81% | 1.93% | 1.06% | 2.89% | 1.22% | 2.65% | 1.28% |
Agenus's average Quarter revenue forecast for Mar 24 based on 1 analysts is $47.17M, with a low forecast of $47.17M, and a high forecast of $47.17M. AGEN's average Quarter revenue forecast represents a -43.71% decrease compared to the company's last Quarter revenue of $83.80M (Dec 23).
Agenus EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-4.36M | $442.00K | $2.14M | $-52.15M | $-52.82M | $-39.41M | $-34.22M | $-34.28M | $-47.28M | $196.81M | $-64.89M | $-36.06M | $-19.57M | $-33.09M | $-31.06M | $-28.94M | $-16.54M | $-33.14M |
| Avg Forecast | $-60.85M | $-58.40M | $-54.73M | $-51.06M | $-27.73M | $-27.71M | $-27.70M | $-27.70M | $-26.11M | $-21.13M | $-40.06M | $-37.59M | $-29.70M | $-15.36M | $-15.23M | $-40.21M | $-14.53M | $-13.06M | $-11.80M | $-43.00M | $-23.82M | $-115.56M | $-12.88M | $-40.71M | $-10.24M | $-8.84M | $-5.89M | $-30.69M | $-8.22M | $-9.85M |
| High Forecast | $-60.85M | $-58.40M | $-54.73M | $-51.06M | $-27.73M | $-27.71M | $-27.70M | $-27.70M | $-26.11M | $-13.95M | $-40.06M | $-30.08M | $-14.15M | $-15.36M | $-15.23M | $-32.17M | $-11.62M | $-13.06M | $-11.80M | $-34.40M | $-23.82M | $-115.56M | $-12.88M | $-32.57M | $-10.24M | $-8.84M | $-5.89M | $-24.55M | $-8.22M | $-9.85M |
| Low Forecast | $-60.85M | $-58.40M | $-54.73M | $-51.06M | $-27.73M | $-27.71M | $-27.70M | $-27.70M | $-26.11M | $-34.42M | $-40.06M | $-45.11M | $-40.70M | $-15.36M | $-15.23M | $-48.25M | $-17.43M | $-13.06M | $-11.80M | $-51.60M | $-23.82M | $-115.56M | $-12.88M | $-48.85M | $-10.24M | $-8.84M | $-5.89M | $-36.83M | $-8.22M | $-9.85M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.15% | -0.03% | -0.14% | 1.30% | 3.64% | 3.02% | 2.90% | 0.80% | 1.99% | -1.70% | 5.04% | 0.89% | 1.91% | 3.75% | 5.28% | 0.94% | 2.01% | 3.37% |
3 analysts predict AGEN's average Quarter EBITDA for Dec 23 to be $-29.70M, with a high of $-14.15M and a low of $-40.70M. This is -6818.62% lower than Agenus's previous annual EBITDA (Sep 23) of $442.00K.
Agenus Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-48.58M | $-62.25M | $-69.07M | $-67.85M | $-97.40M | $-74.28M | $-51.10M | $-63.47M | $-84.18M | $178.55M | $-83.29M | $-53.68M | $-37.61M | $-51.15M | $-47.48M | $-44.67M | $-30.05M | $-45.47M |
| Avg Forecast | $-40.42M | $-42.47M | $-46.29M | $-50.46M | $-70.20M | $-68.23M | $-65.12M | $-61.56M | $-47.07M | $-48.73M | $-22.46M | $-57.74M | $-22.48M | $-82.17M | $-82.14M | $-61.75M | $-15.03M | $-77.51M | $-95.07M | $-66.04M | $-65.10M | $188.77M | $-100.59M | $-60.60M | $-90.94M | $-107.47M | $-112.99M | $-47.38M | $-157.08M | $-157.08M |
| High Forecast | $-40.42M | $-42.47M | $-46.29M | $-50.46M | $-70.20M | $-68.23M | $-65.12M | $-61.56M | $-47.07M | $-19.07M | $-22.46M | $-46.19M | $7.49M | $-82.17M | $-82.14M | $-49.40M | $-12.02M | $-77.51M | $-95.07M | $-52.84M | $-65.10M | $188.77M | $-100.59M | $-48.48M | $-90.94M | $-107.47M | $-112.99M | $-37.91M | $-157.08M | $-157.08M |
| Low Forecast | $-40.42M | $-42.47M | $-46.29M | $-50.46M | $-70.20M | $-68.23M | $-65.12M | $-61.56M | $-47.07M | $-61.23M | $-22.46M | $-69.28M | $-56.21M | $-82.17M | $-82.14M | $-74.10M | $-18.04M | $-77.51M | $-95.07M | $-79.25M | $-65.10M | $188.77M | $-100.59M | $-72.72M | $-90.94M | $-107.47M | $-112.99M | $-56.86M | $-157.08M | $-157.08M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.16% | 0.76% | 0.84% | 1.10% | 6.48% | 0.96% | 0.54% | 0.96% | 1.29% | 0.95% | 0.83% | 0.89% | 0.41% | 0.48% | 0.42% | 0.94% | 0.19% | 0.29% |
Agenus's average Quarter net income forecast for Dec 21 is $-65.10M, with a range of $-65.10M to $-65.10M. AGEN's average Quarter net income forecast represents a -136.46% decrease compared to the company's last Quarter net income of $178.55M (Sep 21).
Agenus SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $21.18M | $18.91M | $20.41M | $18.24M | $25.04M | $18.11M | $18.91M | $18.95M | $21.97M | $21.39M | $16.65M | $16.35M | $20.03M | $14.38M | $14.20M | $10.61M | $12.32M | $11.51M |
| Avg Forecast | $47.83M | $45.89M | $43.02M | $40.13M | $21.79M | $21.78M | $21.77M | $21.77M | $20.52M | $16.60M | $31.48M | $22.64M | $23.34M | $12.07M | $11.97M | $11.40M | $2.92M | $10.26M | $9.27M | $5.85M | $18.72M | $90.82M | $10.12M | $7.21M | $8.05M | $6.94M | $4.63M | $11.26M | $6.46M | $7.74M |
| High Forecast | $47.83M | $45.89M | $43.02M | $40.13M | $21.79M | $21.78M | $21.77M | $21.77M | $20.52M | $27.05M | $31.48M | $27.17M | $31.99M | $12.07M | $11.97M | $11.40M | $3.50M | $10.26M | $9.27M | $5.85M | $18.72M | $90.82M | $10.12M | $7.21M | $8.05M | $6.94M | $4.63M | $13.51M | $6.46M | $7.74M |
| Low Forecast | $47.83M | $45.89M | $43.02M | $40.13M | $21.79M | $21.78M | $21.77M | $21.77M | $20.52M | $10.96M | $31.48M | $18.12M | $11.12M | $12.07M | $11.97M | $11.40M | $2.33M | $10.26M | $9.27M | $5.85M | $18.72M | $90.82M | $10.12M | $7.21M | $8.05M | $6.94M | $4.63M | $9.00M | $6.46M | $7.74M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 1.57% | 1.71% | 1.60% | 8.59% | 1.76% | 2.04% | 3.24% | 1.17% | 0.24% | 1.64% | 2.27% | 2.49% | 2.07% | 3.07% | 0.94% | 1.91% | 1.49% |
Agenus's average Quarter SG&A projection for Mar 24 is $22.64M, based on 1 Wall Street analysts, with a range of $18.12M to $27.17M. The forecast indicates a 6.93% rise compared to AGEN last annual SG&A of $21.18M (Dec 23).
Agenus EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.13 | $-0.16 | $-0.20 | $-0.21 | $-0.35 | $-0.26 | $-0.18 | $-0.25 | $-0.36 | $0.76 | $-0.37 | $-0.27 | $-0.19 | $-0.28 | $-0.28 | $-0.31 | $-0.21 | $-0.33 |
| Avg Forecast | $-1.92 | $-2.02 | $-2.20 | $-2.40 | $-3.33 | $-3.24 | $-3.09 | $-2.92 | $-2.23 | $-2.31 | $-1.07 | $-3.21 | $-1.07 | $-3.90 | $-3.90 | $-4.14 | $-4.35 | $-3.68 | $-4.51 | $-5.84 | $-3.09 | $8.96 | $-4.78 | $-6.02 | $-4.32 | $-5.10 | $-5.36 | $-6.54 | $-7.46 | $-7.46 |
| High Forecast | $-1.92 | $-2.02 | $-2.20 | $-2.40 | $-3.33 | $-3.24 | $-3.09 | $-2.92 | $-2.23 | $-0.91 | $-1.07 | $-3.21 | $0.36 | $-3.90 | $-3.90 | $-4.14 | $-4.35 | $-3.68 | $-4.51 | $-5.84 | $-3.09 | $8.96 | $-4.78 | $-6.02 | $-4.32 | $-5.10 | $-5.36 | $-6.54 | $-7.46 | $-7.46 |
| Low Forecast | $-1.92 | $-2.02 | $-2.20 | $-2.40 | $-3.33 | $-3.24 | $-3.09 | $-2.92 | $-2.23 | $-2.91 | $-1.07 | $-3.21 | $-2.67 | $-3.90 | $-3.90 | $-4.14 | $-4.35 | $-3.68 | $-4.51 | $-5.84 | $-3.09 | $8.96 | $-4.78 | $-6.02 | $-4.32 | $-5.10 | $-5.36 | $-6.54 | $-7.46 | $-7.46 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.12% | 0.04% | 0.05% | 0.05% | 0.08% | 0.07% | 0.04% | 0.04% | 0.12% | 0.08% | 0.08% | 0.04% | 0.04% | 0.05% | 0.05% | 0.05% | 0.03% | 0.04% |
According to 1 Wall Street analysts, Agenus's projected average Quarter EPS for Dec 21 is $-3.09, with a low estimate of $-3.09 and a high estimate of $-3.09. This represents a -506.72% decrease compared to AGEN previous annual EPS of $0.76 (Sep 21).
Agenus Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.53 | $3.67 | 592.45% | Buy |
| ADAP | Adaptimmune Therapeutics | $0.83 | $2.83 | 240.96% | Buy |
| ADCT | ADC Therapeutics SA | $3.02 | $9.33 | 208.94% | Buy |
| PDSB | PDS Bio | $3.23 | $9.00 | 178.64% | Buy |
| AFMD | Affimed | $3.27 | $7.50 | 129.36% | Buy |
| AGEN | Agenus | $4.06 | $8.00 | 97.04% | Hold |
| MREO | Mereo BioPharma Group | $4.01 | $6.75 | 68.33% | Buy |
| VKTX | Viking Therapeutics | $63.14 | $100.50 | 59.17% | Buy |
| LPTX | Leap Therapeutics | $3.67 | $5.50 | 49.86% | Buy |
| EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
| TGTX | TG Therapeutics | $24.36 | $26.40 | 8.37% | Buy |
| MDGL | Madrigal Pharmaceuticals | $331.32 | $315.75 | -4.70% | Buy |
AGEN Forecast FAQ
Is Agenus a good buy?
No, according to 4 Wall Street analysts, Agenus (AGEN) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 25.00% of AGEN's total ratings.
What is AGEN's price target?
Agenus (AGEN) average price target is $8 with a range of $7 to $9, implying a 97.04% from its last price of $4.06. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Agenus stock go up soon?
According to Wall Street analysts' prediction for AGEN stock, the company can go up by 97.04% (from the last price of $4.06 to the average price target of $8), up by 121.67% based on the highest stock price target, and up by 72.41% based on the lowest stock price target.
Can Agenus stock reach $6?
AGEN's average twelve months analyst stock price target of $8 supports the claim that Agenus can reach $6 in the near future.
What are Agenus's analysts' financial forecasts?
Agenus's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $175.63M (high $175.63M, low $175.63M), average EBITDA is $-111M (high $-111M, low $-111M), average net income is $-265M (high $-265M, low $-265M), average SG&A $87.11M (high $87.11M, low $87.11M), and average EPS is $-12.588 (high $-12.588, low $-12.588). AGEN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $356.59M (high $356.59M, low $356.59M), average EBITDA is $-225M (high $-225M, low $-225M), average net income is $-180M (high $-180M, low $-180M), average SG&A $176.86M (high $176.86M, low $176.86M), and average EPS is $-8.529 (high $-8.529, low $-8.529).
Did the AGEN's actual financial results beat the analysts' financial forecasts?
Based on Agenus's last annual report (Dec 2023), the company's revenue was $785.91M, beating the average analysts forecast of $118.49M by 563.25%. Apple's EBITDA was $0, missing the average prediction of $-100M by -100.00%. The company's net income was $0, missing the average estimation of $-249M by -100.00%. Apple's SG&A was $0, missing the average forecast of $58.77M by -100.00%. Lastly, the company's EPS was $0, missing the average prediction of $-13.011 by -100.00%. In terms of the last quarterly report (Dec 2023), Agenus's revenue was $83.8M, beating the average analysts' forecast of $47.05M by 78.09%. The company's EBITDA was $-4.359M, missing the average prediction of $-29.696M by -85.32%. Agenus's net income was $-48.582M, beating the average estimation of $-22.484M by 116.08%. The company's SG&A was $21.18M, missing the average forecast of $23.34M by -9.26%. Lastly, the company's EPS was $-0.13, missing the average prediction of $-1.067 by -87.82%